Meeting
2013 ASCO Annual Meeting
Clinical experience with exemestane in postmenopausal women at increased risk of breast cancer.
Authors
Mia Sorkin
Yale University School of Public Health, New Haven, CT
Mia Sorkin , Donna Lapolt , Lajos Pusztai , Erin Wysong Hofstatter
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Cancer Prevention/Epidemiology
Track
Cancer Prevention/Epidemiology
Sub Track
Cancer Prevention
Citation
J Clin Oncol 31, 2013 (suppl; abstr 1565)
DOI
10.1200/jco.2013.31.15_suppl.1565
Abstract #
1565
Poster Bd #
5B
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Assessment and management of bone health in women treated with adjuvant anastrozole in the DATA study.
First Author: Irene Van Hellemond
Poster
2017 ASCO Annual Meeting
Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial.
First Author: Francesco Perrone
Poster
2014 ASCO Annual Meeting
Cost-effectiveness of aromatase inhibitors versus selective estrogen-receptor modulators for breast cancer prevention in postmenopausal women.
First Author: Amy Grace Groom
Poster
2012 Breast Cancer Symposium
A program to increase use of chemoprevention for women with high-risk breast lesions.
First Author: Constance Roche